Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation

摘要

FOXD2-AS1 mRNA expression in primary head and neck squamous cell carcinoma (HNSC) tissues (tumor) and matched normal tissues (normal) from UALCAN webserver. , FOXD2-AS1 mRNA expression in primary HNSC tissues from patients with different clinical stages and tumor grades from UALCAN webserver, respectively. – Prognostic value of FOXD2-AS1 expression in HNSC patients by using online Kaplan–Meier Plotter analysis. Overall survival (OS) of 259 stage IV HNSC patients according the FOXD2-AS1 status. The median value of FOXD2-AS1 expression levels in these 259 tissues was used to stratify the high and low expression levels of FOXD2-AS1. , OS of 499 HNSC patients according the FOXD2-AS1 status. The median value and the best cutoff value of FOXD2-AS1 expression levels in these 499 tissues was used to stratify the high and low expression levels of FOXD2-AS1, respectively. Real-time PCR analysis of FOXD2-AS1 expression in 24 primary laryngeal squamous cancer tissues and matched adjacent normal tissues. FOXD2-AS1 expression were significantly increased in 21 out of 24 cases of tumor comparing with paired normal tissues. FOXD2-AS1 mRNA expression in primary HNSC tissues from patients with different clinical stages. FOXD2-AS1 mRNA expression in primary HNSC tissues from patients with different relapse status. Transcript levels were normalized to GAPDH expression. *  P P